Many Investors Still Treating Gilead: 4 Launches This Year Could Prove Them Wrong
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Before investing all your savings, evaluate your financial goals and risk tolerance. Make informed decisions to safeguard your future.
23,659 articlesGilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Chip stocks were crashing after a period of strong earnings, leaving many investors puzzled. This article unpacks why...
AI data centers are expanding fast, and one networking stock stands out as a compelling buy near $150. This guide bre...
For investors seeking steady income, certain dividend stocks worth more today offer reliable payouts and potential pr...
If you’re building a decade-long plan, these energy stocks worth holding offer durable cash flow, solid dividends, an...
Choosing the right ETF can feel like choosing the right map for a long journey. This guide breaks down which better E...
AI sparks a data deluge, and storage stocks ride the wave. This guide breaks down how this storage stock more opportu...
Investors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
When a feud becomes a marketing engine, money talks louder than records. This feature examines how T.I. targets Cent ...
Looking for tech stocks with staying power? This guide breaks down how to pick what best tech stocks to hold for the ...
A high-stakes legal clash between Archer Aviation and Joby could swing how investors price the whole eVTOL space. Her...
Chewy has faced a rough year, with shares falling and growth challenges ahead. Yet, a closer look under the hood show...